LONA LeonaBio, Inc.

NASDAQ
$3.47

LeonaBio, Inc. (LONA) is confirmed to report earnings on November 16, 2026, after the market close. The consensus earnings estimate is a loss of $0.62 per share.

LeonaBio Missed Consensus Estimates
Monday, November 16, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.62)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.86

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About LeonaBio, Inc.

LeonaBio Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. Its lead drug candidates include lasofoxifene and ATH-1105. LeonaBio Inc., formerly known as Athira Pharma Inc., is headquartered in the Seattle, Washington.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.